The basic and clinical research regarding development of combinationalchemotherapy with nitric oxide donating drugs for non-small cell lung cancer

点击翻译按钮获取中文摘要

In basic science, I showed that nitroglycerin (GTN) significantly reduced HIF-1 alpha, P-glycoprotein, VEGF, P-Akt, and P-CREB in tumor tissues in vivo, resulting in enhancing chemosensitivity of cancer cells to anti-cancer drugs including cisplatin and docetaxel. I started and have been performing three clinical trials regarding combinational chemotherapy with GTN for the next phase III trials, as following : 1) Randomized multicenter phase II trial comparing paclitaxel and carboplatin with GTN with paclitaxel and carboplatin alone in patients with previously untreated advanced non-small cell lung cancer (NSCLC) ; 2) Single arm phase II trial of amrubicin and GTN in patients with previously treated advanced NSCLC as third regimen ; 3) Single arm phase II trial of docetaxel and GTN in elderly patients with previously untreated advanced NSCLC.